Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizu...

書誌詳細
主要な著者:	Pavord, I, Chanez, P, Criner, G, Kerstjens, H, Korn, S, Lugogo, N, Martinot, J, Sagara, H, Albers, F, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S, Sciurba, F
フォーマット:	Journal article
言語:	English
出版事項:	Massachusetts Medical Society 2017

類似資料

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
著者:: Pavord, I, 等
出版事項: (2017)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
著者:: Bafadhel, M, 等
出版事項: (2018)

Mepolizumab for eosinophilic COPD
著者:: Sciurba, F, 等
出版事項: (2018)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
著者:: Chapman, K, 等
出版事項: (2018)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
著者:: Gunsoy, N, 等
出版事項: (2017)

Mepolizumab treatment in patients with severe eosinophilic asthma.
著者:: Ortega, H, 等
出版事項: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
著者:: Bel, E, 等
出版事項: (2014)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
著者:: Shrimanker, R, 等
出版事項: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
著者:: Mkorombindo T, 等
出版事項: (2019-08-01)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
著者:: Pavord, I, 等
出版事項: (2012)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
著者:: Bel, E, 等
出版事項: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
著者:: Steven W. Yancey, 等
出版事項: (2019-09-01)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
著者:: Ortega, H, 等
出版事項: (2016)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
著者:: Yancey, S, 等
出版事項: (2016)

Mepolizumab in refractory eosinophilic asthma.
著者:: Pavord, I, 等
出版事項: (2010)

Mepolizumab, quality of life, and severe eosinophilic asthma.
著者:: Pavord, I
出版事項: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Howell, I, 等
出版事項: (2024)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
著者:: Prazma CM, 等
出版事項: (2021-06-01)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
著者:: Ian D. Pavord, 等
出版事項: (2022-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Imran Howell, 等
出版事項: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
著者:: Terufumi Shimoda, 等
出版事項: (2017-07-01)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
著者:: Wechsler, M, 等
出版事項: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
著者:: Moran, AM, 等
出版事項: (2020)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
著者:: Haldar, P, 等
出版事項: (2009)

Response to mepolizumab treatment is sustained across 4-weekly dosing periods
著者:: Ian D. Pavord, 等
出版事項: (2020-09-01)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
著者:: Mi-Kyeong Kim, 等
出版事項: (2021-03-01)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
著者:: Frank C. Albers, 等
出版事項: (2019-07-01)

Treatment of eosinophilic myositis with mepolizumab
著者:: Saadia Waheed, 等
出版事項: (2018-01-01)

GLUCOLD, eosinophils and chronic obstructive pulmonary disease
著者:: Pavord, I
出版事項: (2018)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
著者:: Shrimanker, R, 等
出版事項: (2017)

Biomarkers for severe eosinophilic asthma.
著者:: Yancey, S, 等
出版事項: (2017)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
著者:: Menzella F, 等
出版事項: (2016-06-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
著者:: Shrimanker, R, 等
出版事項: (2017)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
著者:: Moran, A, 等
出版事項: (2020)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
著者:: Benjamin Terrier, 等
出版事項: (2023-07-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
著者:: Chio Sakai, 等
出版事項: (2024-07-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
著者:: Nina B. Curkovic, MD, 等
出版事項: (2024-11-01)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
著者:: Ravi Ranjan Pradhan, 等
出版事項: (2019-01-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
著者:: Ryota Otoshi, 等
出版事項: (2020-03-01)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
著者:: Ian Pavord, 等
出版事項: (2023-04-01)